SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001011438-23-000501
Filing Date
2023-08-10
Accepted
2023-08-10 09:20:20
Documents
1
Group Members
ATG CAPITAL MANAGEMENT, LLCGABRIEL GLIKSBERG

Document Format Files

Seq Description Document Type Size
1 form_sc13da-forte.htm SC 13D/A 63747
  Complete submission text file 0001011438-23-000501.txt   65500
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89959 | Film No.: 231157486
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ATG CAPITAL MANAGEMENT, LLC 805 N. MILWAUKEE AVE., STE. 301 CHICAGO IL 60642
Business Address C/O ATG CAPITAL MANAGEMENT, LLC 805 N. MILWAUKEE AVE., STE. 301 CHICAGO IL 60642 (786) 519-0995
ATG Fund II LLC (Filed by) CIK: 0001940093 (see all company filings)

IRS No.: 882296572 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A